ASLAN Inks Licensing Deal With Zenyaku Kogyo To Commercialize Eblasakimab In Japan
Portfolio Pulse from Nabaparna Bhattacharya
ASLAN Pharmaceuticals has signed a licensing deal with Zenyaku Kogyo to develop and commercialize Eblasakimab in Japan. ASLAN will receive up to $15 million in upfront and near-term payments, and up to an additional $123.5 million based on development and commercial milestones, plus tiered royalties on sales.
June 22, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ASLAN Pharmaceuticals signed a licensing deal with Zenyaku Kogyo for Eblasakimab in Japan, potentially receiving up to $138.5 million in payments.
The licensing deal with Zenyaku Kogyo will provide ASLAN Pharmaceuticals with upfront and near-term payments, as well as additional payments based on development and commercial milestones. This deal is expected to have a positive impact on ASLAN's stock price in the short term due to the potential revenue and partnership with a leading Japanese pharmaceutical company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100